Medical device company Amend Surgical has received funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center to support the development of its Tissure suture-less nerve repair device.
The company will use the funds for the commercialisation of a novel, suture-less solution to repair peripheral nerves.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Tissure is a resorbable hydrogel membrane with a chitosan-based adhesive. It can be used for the replacement of the suture to repair peripheral nerve injuries.
Amend Surgical CEO Robby Lane said: “We are committed to providing clinicians innovative and effective options for the treatment of oral tissue wounds including the repair of peripheral nerves.
“Our initial commercialisation efforts will be focused on oral surgery, but we anticipate that Tissure will fill a significant unmet need in the entire peripheral nerve market.”
In 2020, Amend Surgical secured the exclusive licence for the Tissure technology from the Wyss Institute at Harvard University.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe unique properties of Tissure enable it to stick to wet tissue at more than five times the adhesion energy of surgical glues. Tissure can also stretch through a range of motion.
The hydrogel membrane showcases a pullout strength while stuck to a nerve of more than two newtons and will resorb throughout nerve healing. It can stick to a range of wet surfaces including nerve tissue and collagen.
Amend Surgical previously finalised a funding agreement with the Institute for Commercialization of Florida Technology in May last year.
